November 3, 2020
|
Outlook Therapeutics Completes Patient Enrollment of Open-Label Safety Study for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
|
|
October 22, 2020
|
Outlook Therapeutics to Present at the Virtual Investor KOL Roundtable
|
|
October 13, 2020
|
Outlook Therapeutics Announces Initiation of Supplemental Open-Label Safety Study for ONS-5010 / LYTENAVA™ (bevacizumab-vikg)
|
|
October 7, 2020
|
Outlook Therapeutics to Present at the Virtual BIO Investor Forum Digital
|
|
September 30, 2020
|
Outlook Therapeutics Provides Update on Progress Towards First Approved Ophthalmic Formulation of Bevacizumab-vikg for Advanced Macular Degeneration
|
|
September 8, 2020
|
Outlook Therapeutics to Present at Two Upcoming Investor Conferences
|
|
August 26, 2020
|
Outlook Therapeutics Reports Topline Results and Positive Proof-of-Concept for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) from NORSE 1
|
|
August 14, 2020
|
Outlook Therapeutics Reports Financial Results for the Third Quarter of Fiscal Year 2020 and Provides Corporate Update
|
|
July 17, 2020
|
Outlook Therapeutics Announces Closing of $1.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
|
|
July 7, 2020
|
Outlook Therapeutics Completes Patient Enrollment for NORSE 2 Study of ONS-5010 / LYTENAVA™ (bevacizumab-vikg)
|
|